Genzyme's surgical mesh gets US clearance:
This article was originally published in Clinica
Executive Summary
Genzyme Surgical Products has received 510(k) clearance from the US FDA to market its Sepramesh Biosurgical Composite for use in hernia repair procedures. The surgical mesh is designed to be sutured in place along the abdominal wall providing support and strength to the hernia repair. Sepramesh contains a bioresorbable barrier that separates the mesh from underlying tissue and organ surfaces to minimise attachment to the mesh. This offers significant advantages over traditional mesh products, the Cambridge, Massachusetts-based company said.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.